<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113241</url>
  </required_header>
  <id_info>
    <org_study_id>DAPA-MS</org_study_id>
    <nct_id>NCT02113241</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion</brief_title>
  <official_title>Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult&#xD;
      population suffers the disease.&#xD;
&#xD;
      Dapagliflozin is an inhibitor of the sodium-glucose co-transporter SGLT2 in the kidney and is&#xD;
      a novel treatment for diabetes type 2. Some studies indicate that SGLT2 inhibitors have&#xD;
      benefits on blood pressure, triglycerides levels and help to raise the levels of high density&#xD;
      lipoproteins cholesterol (c-HDL).&#xD;
&#xD;
      The aim of this study is to evaluate the effect of dapagliflozin on metabolic syndrome,&#xD;
      insulin sensitivity and insulin secretion.&#xD;
&#xD;
      The investigators hypothesis is that the administration of dapagliflozin modifies the&#xD;
      metabolic syndrome, insulin sensitivity and insulin secretion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical trial its going to carry out in 24&#xD;
      patients with a diagnosis of metabolic syndrome in accordance with the International Diabetes&#xD;
      Federation (IDF). Waist circumference, glucose, insulin levels, lipid profile, creatinine and&#xD;
      acid uric are going to be load after a 75 g of dextrose load.&#xD;
&#xD;
      12 patients will receive Forxiga (dapagliflozin), 10 mg, one per day before breakfast during&#xD;
      3 months.&#xD;
&#xD;
      The remaining 12 patients will receive placebo at the same dose.&#xD;
&#xD;
      There will be calculated Area Under the Curve of glucose and insulin, total insulin secretion&#xD;
      (insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin&#xD;
      sensitivity (Matsuda index).&#xD;
&#xD;
      This protocol it's already approved by the local ethics committee and written informed&#xD;
      consent it's going to be obtained from all volunteers.&#xD;
&#xD;
      Results will be presented as mean and standard deviation. Intra and inter group differences&#xD;
      are going to be tested using the Wilcoxon signed-rank and Mann-Whitney U-test respectively;&#xD;
      p≤0.05 it's going to be considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Waist Circumference at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The waist circumference is going to be evaluated at week 12 with a flexible tape with standardized techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides Levels at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The triglycerides levels are going to be evaluated at week 12 with enzymatic-colorimetric techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Density Lipoprotein (c-HDL) Levels at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The c-HDL levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Levels at Minute 0 at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The fasting glucose (0') levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Blood Pressure at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The systolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The diastolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulinogenic Index (Total Insulin Secretion) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stumvoll Index (First Phase of Insulin Secretion) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matsuda Index (Total Insulin Sensitivity) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The weight it's going to be measured at week 12 with a bioimpedance balance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The Body Mass index it's going to be calculated at week 12 with the Quetelet index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Mass at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The fat mass is going to be evaluated at week 12 through bioimpedance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The total cholesterol will be estimated by standardized techniques at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoproteins (c-LDL) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The c-LDL levels are going to be measured at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) at Week 12.</measure>
    <time_frame>Week 12.</time_frame>
    <description>The ALT hepatic transaminase levels are going to be measured at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The hepatic transaminase AST will be evaluated with standardized methods at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine at Week 12.</measure>
    <time_frame>Week 12.</time_frame>
    <description>The creatinine levels are going to be measured at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric Acid at Week 12.</measure>
    <time_frame>Week 12.</time_frame>
    <description>The uric acid levels are going to be measured at week 12 with standardized techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Glucose at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The AUC of glucose will be calculated from the glucose values obtained from the minuted oral glucose tolerance curve at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Insulin at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The AUC will be calculated from the insulin values obtained from the minuted oral glucose tolerance curve at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose at Minute 30 at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The glucose at minute 30 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose at Minute 60 at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The glucose at minute 60 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose at Minute 90 at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The glucose at minute 90 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose at Minute 120 at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>The glucose at minute 120 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients both sexes&#xD;
&#xD;
          -  Age between 30 and 60 years&#xD;
&#xD;
          -  Metabolic Syndrome according to the IDF criteria&#xD;
&#xD;
          -  Waist circumference&#xD;
&#xD;
          -  Man ≥90 cm&#xD;
&#xD;
          -  Woman ≥80 cm&#xD;
&#xD;
          -  And two of the following criteria&#xD;
&#xD;
          -  High density lipoprotein&#xD;
&#xD;
          -  Man ≤40 mg/dL&#xD;
&#xD;
          -  Woman ≤50 mg/dL&#xD;
&#xD;
          -  Fasting glucose ≥100 mg/dL&#xD;
&#xD;
          -  Triglycerides ≥150 mg/dL&#xD;
&#xD;
          -  Blood pressure ≥130/85 mmHg&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy&#xD;
&#xD;
          -  Women under lactation and/or puerperium&#xD;
&#xD;
          -  Hypersensibility to SGLT2 inhibitors&#xD;
&#xD;
          -  Physical impossibility for taking pills&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, heart or thyroid diseased&#xD;
&#xD;
          -  Previous treatment for the metabolic syndrome components&#xD;
&#xD;
          -  Body Mass Index ≥39.9 kg/m2&#xD;
&#xD;
          -  Fasting glucose ≥126 mg/dL&#xD;
&#xD;
          -  Triglycerides ≥500 mg/dL&#xD;
&#xD;
          -  Total cholesterol ≥240 mg/dL&#xD;
&#xD;
          -  Low density lipoprotein (c-LDL) ≥190 mg/dL&#xD;
&#xD;
          -  Blood Pressure ≥140/90 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.</citation>
    <PMID>22238392</PMID>
  </reference>
  <reference>
    <citation>Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012 Jul;35(7):1473-8. doi: 10.2337/dc11-1693. Epub 2012 Mar 23.</citation>
    <PMID>22446170</PMID>
  </reference>
  <reference>
    <citation>Chao EC. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evid. 2012;7:21-8. doi: 10.2147/CE.S16359. Epub 2012 Jun 1.</citation>
    <PMID>22701099</PMID>
  </reference>
  <reference>
    <citation>Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. Review.</citation>
    <PMID>24105299</PMID>
  </reference>
  <reference>
    <citation>Yang L, Li H, Li H, Bui A, Chang M, Liu X, Kasichayanula S, Griffen SC, Lacreta FP, Boulton DW. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther. 2013 Aug;35(8):1211-1222.e2. doi: 10.1016/j.clinthera.2013.06.017. Epub 2013 Aug 2.</citation>
    <PMID>23910664</PMID>
  </reference>
  <reference>
    <citation>Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8.</citation>
    <PMID>19996149</PMID>
  </reference>
  <reference>
    <citation>Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013 Sep;76(3):432-44. doi: 10.1111/bcp.12056.</citation>
    <PMID>23210765</PMID>
  </reference>
  <reference>
    <citation>Kilov G, Leow S, Thomas M. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes. Aust Fam Physician. 2013 Oct;42(10):706-10. Review.</citation>
    <PMID>24130972</PMID>
  </reference>
  <reference>
    <citation>Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013 May;15(5):432-40. doi: 10.1111/dom.12047. Epub 2013 Jan 25.</citation>
    <PMID>23194084</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010 Jun;12(6):510-6. doi: 10.1111/j.1463-1326.2010.01216.x.</citation>
    <PMID>20518806</PMID>
  </reference>
  <reference>
    <citation>Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.</citation>
    <PMID>23668478</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21.</citation>
    <PMID>20566676</PMID>
  </reference>
  <reference>
    <citation>Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 Feb;16(2):159-69. doi: 10.1111/dom.12189. Epub 2013 Aug 29.</citation>
    <PMID>23906445</PMID>
  </reference>
  <reference>
    <citation>Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 Feb;124(2):509-14. doi: 10.1172/JCI70704. Epub 2014 Jan 27. Erratum in: J Clin Invest. 2014 May 1;124(5):2287.</citation>
    <PMID>24463448</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <results_first_submitted>August 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>forxiga</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="8.4"/>
                    <measurement group_id="B2" value="49.5" spread="6.0"/>
                    <measurement group_id="B3" value="46.4" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight (kg)</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.7" spread="12.9"/>
                    <measurement group_id="B2" value="80.0" spread="11.3"/>
                    <measurement group_id="B3" value="81.4" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="3.5"/>
                    <measurement group_id="B2" value="31.5" spread="3.1"/>
                    <measurement group_id="B3" value="32.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat mass (kg)</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="8.5"/>
                    <measurement group_id="B2" value="32.6" spread="8.2"/>
                    <measurement group_id="B3" value="32.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference (WC) (cm)</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.5" spread="10.1"/>
                    <measurement group_id="B2" value="96.1" spread="7.2"/>
                    <measurement group_id="B3" value="98.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (SBP) (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121" spread="13"/>
                    <measurement group_id="B2" value="126" spread="10"/>
                    <measurement group_id="B3" value="123.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure (DBP) (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="12"/>
                    <measurement group_id="B2" value="79" spread="10"/>
                    <measurement group_id="B3" value="78.2" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose at minute 0 (0') (mmol/L)</title>
          <description>The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood samples were taken at the basal (minute 0') and at the minutes 30 (30'), 60 (60'), 90 (90') and 120 (120') after a 75 g oral dextrose load.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" spread="0.5"/>
                    <measurement group_id="B2" value="5.8" spread="0.6"/>
                    <measurement group_id="B3" value="6.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose at minute 30 (30') (mmol/L)</title>
          <description>The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood samples were taken at the basal (minute 0') and at the minutes 30 (30'), 60 (60'), 90 (90') and 120 (120') after a 75 g oral dextrose load.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" spread="2.6"/>
                    <measurement group_id="B2" value="9.1" spread="2.1"/>
                    <measurement group_id="B3" value="9.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose at minute 60 (60') (mmol/L)</title>
          <description>The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood samples were taken at the basal (minute 0') and at the minutes 30 (30'), 60 (60'), 90 (90') and 120 (120') after a 75 g oral dextrose load.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.0" spread="3.8"/>
                    <measurement group_id="B2" value="10.4" spread="2.6"/>
                    <measurement group_id="B3" value="11.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose at minute 90 (90') (mmol/L)</title>
          <description>The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood samples were taken at the basal (minute 0') and at the minutes 30 (30'), 60 (60'), 90 (90') and 120 (120') after a 75 g oral dextrose load.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="3.1"/>
                    <measurement group_id="B2" value="9.1" spread="2.6"/>
                    <measurement group_id="B3" value="10.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose at minute 120 (120') (mmol/L)</title>
          <description>The blood samples were taken after the insertion of a catheter as an open path to facilitate the procedure. Blood samples were taken at the basal (minute 0') and at the minutes 30 (30'), 60 (60'), 90 (90') and 120 (120') after a 75 g oral dextrose load.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="2.1"/>
                    <measurement group_id="B2" value="7.6" spread="2.2"/>
                    <measurement group_id="B3" value="8.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol (mmol/L)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="0.7"/>
                    <measurement group_id="B2" value="4.9" spread="1.0"/>
                    <measurement group_id="B3" value="5.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (mmol/L)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="1.4"/>
                    <measurement group_id="B2" value="2.0" spread="0.7"/>
                    <measurement group_id="B3" value="2.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL-cholesterol (mmol/L)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" spread="0.2"/>
                    <measurement group_id="B2" value="1.2" spread="0.3"/>
                    <measurement group_id="B3" value="1.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-cholesterol (mmol/L)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="1.0"/>
                    <measurement group_id="B2" value="2.8" spread="0.9"/>
                    <measurement group_id="B3" value="2.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area Under the Curve (AUC) glucose (mmol*hr/L)</title>
          <units>mmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1235" spread="304"/>
                    <measurement group_id="B2" value="1060" spread="233"/>
                    <measurement group_id="B3" value="1148.3" spread="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area Under the Curve (AUC) insulin (pmol*hr/L)</title>
          <units>pmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103910" spread="55167"/>
                    <measurement group_id="B2" value="106683" spread="41787"/>
                    <measurement group_id="B3" value="105297" spread="47884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulinogenic index (total insulin secretion)</title>
          <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.83" spread="0.64"/>
                    <measurement group_id="B2" value="0.98" spread="0.46"/>
                    <measurement group_id="B3" value="0.91" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stumvoll Index (first phase of insulin secretion)</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1566" spread="1137"/>
                    <measurement group_id="B2" value="1675" spread="819"/>
                    <measurement group_id="B3" value="1620.8" spread="971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Matsuda Index (insulin sensitivity)</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="1.1"/>
                    <measurement group_id="B2" value="1.8" spread="0.8"/>
                    <measurement group_id="B3" value="1.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine (mmol/L)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.06" spread="0.02"/>
                    <measurement group_id="B2" value="0.07" spread="0.02"/>
                    <measurement group_id="B3" value="0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uric acid (umol/L)</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267.7" spread="95.2"/>
                    <measurement group_id="B2" value="315.2" spread="101.1"/>
                    <measurement group_id="B3" value="291.5" spread="101.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase (ALT)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="31.6"/>
                    <measurement group_id="B2" value="37.9" spread="17.1"/>
                    <measurement group_id="B3" value="44.4" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate aminotransferase (AST)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.9" spread="19.1"/>
                    <measurement group_id="B2" value="28.8" spread="17.7"/>
                    <measurement group_id="B3" value="33.4" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Waist Circumference at Week 12.</title>
        <description>The waist circumference is going to be evaluated at week 12 with a flexible tape with standardized techniques.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference at Week 12.</title>
          <description>The waist circumference is going to be evaluated at week 12 with a flexible tape with standardized techniques.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="8.9"/>
                    <measurement group_id="O2" value="97.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.089</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides Levels at Week 12.</title>
        <description>The triglycerides levels are going to be evaluated at week 12 with enzymatic-colorimetric techniques.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides Levels at Week 12.</title>
          <description>The triglycerides levels are going to be evaluated at week 12 with enzymatic-colorimetric techniques.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.8"/>
                    <measurement group_id="O2" value="1.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.248</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High Density Lipoprotein (c-HDL) Levels at Week 12.</title>
        <description>The c-HDL levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein (c-HDL) Levels at Week 12.</title>
          <description>The c-HDL levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.2"/>
                    <measurement group_id="O2" value="1.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.161</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.079</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Levels at Minute 0 at Week 12.</title>
        <description>The fasting glucose (0') levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
        <time_frame>Week 12</time_frame>
        <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Levels at Minute 0 at Week 12.</title>
          <description>The fasting glucose (0') levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.</description>
          <population>All participants, including those who dropped out before the end were taken into account for statistical analysis (intention to treat)</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="1.1"/>
                    <measurement group_id="O2" value="5.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.067</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.918</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure at Week 12.</title>
        <description>The systolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 12.</title>
          <description>The systolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" spread="10"/>
                    <measurement group_id="O2" value="121" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.128</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.454</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Blood Pressure at Week 12.</title>
        <description>The diastolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 12.</title>
          <description>The diastolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="8"/>
                    <measurement group_id="O2" value="79" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.433</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.407</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulinogenic Index (Total Insulin Secretion) at Week 12.</title>
        <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulinogenic Index (Total Insulin Secretion) at Week 12.</title>
          <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.11"/>
                    <measurement group_id="O2" value="0.99" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.826</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stumvoll Index (First Phase of Insulin Secretion) at Week 12.</title>
        <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Stumvoll Index (First Phase of Insulin Secretion) at Week 12.</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1463" spread="879"/>
                    <measurement group_id="O2" value="2198" spread="996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.791</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.413</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matsuda Index (Total Insulin Sensitivity) at Week 12.</title>
        <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at week 12.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Index (Total Insulin Sensitivity) at Week 12.</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at week 12.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.4"/>
                    <measurement group_id="O2" value="1.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.075</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.432</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight at Week 12.</title>
        <description>The weight it's going to be measured at week 12 with a bioimpedance balance.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight at Week 12.</title>
          <description>The weight it's going to be measured at week 12 with a bioimpedance balance.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="12.8"/>
                    <measurement group_id="O2" value="79.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.835</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index at Week 12</title>
        <description>The Body Mass index it's going to be calculated at week 12 with the Quetelet index.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index at Week 12</title>
          <description>The Body Mass index it's going to be calculated at week 12 with the Quetelet index.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="3.6"/>
                    <measurement group_id="O2" value="32.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.778</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Mass at Week 12.</title>
        <description>The fat mass is going to be evaluated at week 12 through bioimpedance.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Mass at Week 12.</title>
          <description>The fat mass is going to be evaluated at week 12 through bioimpedance.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="9.2"/>
                    <measurement group_id="O2" value="34.4" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.338</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.309</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol at Week 12</title>
        <description>The total cholesterol will be estimated by standardized techniques at week 12.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol at Week 12</title>
          <description>The total cholesterol will be estimated by standardized techniques at week 12.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.7"/>
                    <measurement group_id="O2" value="4.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.563</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoproteins (c-LDL) at Week 12</title>
        <description>The c-LDL levels are going to be measured at week 12 with standardized techniques.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoproteins (c-LDL) at Week 12</title>
          <description>The c-LDL levels are going to be measured at week 12 with standardized techniques.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.5"/>
                    <measurement group_id="O2" value="2.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.850</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.206</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) at Week 12.</title>
        <description>The ALT hepatic transaminase levels are going to be measured at week 12 with standardized techniques.</description>
        <time_frame>Week 12.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) at Week 12.</title>
          <description>The ALT hepatic transaminase levels are going to be measured at week 12 with standardized techniques.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="15.9"/>
                    <measurement group_id="O2" value="38.1" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.950</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) at Week 12.</title>
        <description>The hepatic transaminase AST will be evaluated with standardized methods at week 12</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) at Week 12.</title>
          <description>The hepatic transaminase AST will be evaluated with standardized methods at week 12</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="14.5"/>
                    <measurement group_id="O2" value="29.5" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.454</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine at Week 12.</title>
        <description>The creatinine levels are going to be measured at week 12 with standardized techniques.</description>
        <time_frame>Week 12.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine at Week 12.</title>
          <description>The creatinine levels are going to be measured at week 12 with standardized techniques.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.01"/>
                    <measurement group_id="O2" value="0.05" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.652</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uric Acid at Week 12.</title>
        <description>The uric acid levels are going to be measured at week 12 with standardized techniques.</description>
        <time_frame>Week 12.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Uric Acid at Week 12.</title>
          <description>The uric acid levels are going to be measured at week 12 with standardized techniques.</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.9" spread="55.3"/>
                    <measurement group_id="O2" value="339.0" spread="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.254</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.787</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Glucose at Week 12.</title>
        <description>The AUC of glucose will be calculated from the glucose values obtained from the minuted oral glucose tolerance curve at week 12</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Glucose at Week 12.</title>
          <description>The AUC of glucose will be calculated from the glucose values obtained from the minuted oral glucose tolerance curve at week 12</description>
          <units>mmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1153" spread="280"/>
                    <measurement group_id="O2" value="1129" spread="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.129</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.365</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Insulin at Week 12.</title>
        <description>The AUC will be calculated from the insulin values obtained from the minuted oral glucose tolerance curve at week 12</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Insulin at Week 12.</title>
          <description>The AUC will be calculated from the insulin values obtained from the minuted oral glucose tolerance curve at week 12</description>
          <units>pmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45016" spread="22147"/>
                    <measurement group_id="O2" value="119704" spread="46872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.175</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose at Minute 30 at Week 12.</title>
        <description>The glucose at minute 30 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose at Minute 30 at Week 12.</title>
          <description>The glucose at minute 30 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="2.0"/>
                    <measurement group_id="O2" value="10.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.392</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.123</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose at Minute 60 at Week 12.</title>
        <description>The glucose at minute 60 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose at Minute 60 at Week 12.</title>
          <description>The glucose at minute 60 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="3.1"/>
                    <measurement group_id="O2" value="11.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.176</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.268</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose at Minute 90 at Week 12.</title>
        <description>The glucose at minute 90 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose at Minute 90 at Week 12.</title>
          <description>The glucose at minute 90 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="3.5"/>
                    <measurement group_id="O2" value="9.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.462</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose at Minute 120 at Week 12.</title>
        <description>The glucose at minute 120 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin</title>
            <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose at Minute 120 at Week 12.</title>
          <description>The glucose at minute 120 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="2.1"/>
                    <measurement group_id="O2" value="8.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.346</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis between before and after the intervention</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 12 weeks of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin</title>
          <description>Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Dapagliflozin: Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo capsules, 10 mg, one per day before breakfast during 90 days.&#xD;
Placebo: Placebo capsules, 10 mg, one per day before breakfast during 90 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. MANUEL GONZALEZ ORTIZ</name_or_title>
      <organization>INSTITUTO DE TERAPEUTICA EXPERIMENTAL Y CLINICA, UNIVERSITY OF GUADALAJARA</organization>
      <phone>+52 3310585200 ext 34212</phone>
      <email>uiec@prodigy.net.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

